THE NEW YORK GENOME CENTER received a $100 million challenge grant from the Simons Foundation and The Carson Family Charitable Trust. The two organizations will match every dollar that NYGC raises over the course of the next three years. The Simons Foundation is chaired by James Simons, who also serves as an NYGC board director.... […]
MYLIN TORRES was named director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University. She succeeds Ruth O’Regan, who now heads the University of Wisconsin Division of Hematology and Oncology. Torres is an associate professor in Emory’s Department of Radiation Oncology and a member of Winship’s Cancer Prevention and Control Program.... […]
MARY-CLAIRE KING was awarded the Szent-Györgyi Prize for Progress in Cancer Research. King’s research was recognized by the National Foundation for Cancer Research for providing the first evidence of genetic predisposition to breast cancer. She is the American Cancer Society Research Professor of Genetics and Medicine (Medical Genetics) at the University of Washington in Seattle.... […]
FDA granted a Breakthrough Therapy Designation to venetoclax in combination with rituximab for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
JAMES WILLSON was named chief scientific officer of the Cancer Prevention and Research Institute of Texas, effective March 1. Willson is the associate dean of oncology programs, and professor and director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center.
FDA granted Priority Review to lenvatinib for the treatment of patients with unresectable advanced or metastatic renal cell carcinoma in combination with everolimus following one prior vascular endothelial growth factor-targeted therapy. FDA previously granted lenvatinib Breakthrough Therapy designation for this investigational indication. “With the FDA’s acceptance of this supplemental application, we are one step closer... […]
Debiopharm International SA announced a collaboration in order to supply triptorelin pamoate 3.75 mg one-month formulation for patients suffering from salivary gland cancer participating in a clinical study sponsored by the European Organisation for Research and Treatment of Cancer.
Health Canada granted conditional approval of Blincyto (blinatumomab) for the treatment of adults with Philadelphia chromosome-negative relapsed or refractory B precursor acute lymphoblastic leukemia.
MD Anderson Cancer Center and DelMar Pharmaceuticals Inc. entered into a collaboration to accelerate the clinical development of DelMar's lead anti-cancer candidate, VAL-083, for the treatment of glioblastoma multiforme.
THE COMMUNITY ONCOLOGY ALLIANCE elected members to its board of directors and officers to its executive committee.
